CIK 0001789972 · Non-accelerated filer<br>Smaller reporting company
Cullinan Therapeutics, Inc.
Sign in to watch- Ticker
- CGEM
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 813879991
- Phone
- 617-410-4650
- Business address
- ONE MAIN STREET, SUITE 1350, CAMBRIDGE, MA, 02142
- Former names
- Cullinan Oncology, Inc., Cullinan Management, Inc., Cullinan Oncology, LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $222,000
- in 2 filings, $222K under 10b5-1 plans
Net −$222,000. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-08-10 | Zawel Leigh See Remarks | Sale | −3,191 | $27.34 | $87K | 123,459 |
| 2021-08-10 | Zawel Leigh See Remarks | Sale | −1,817 | $28.49 | $52K | 121,642 |
| 2021-08-10 | Baeuerle Patrick See Remarks | Option exercise | +11,000 | $4.30 | $47K | 11,000 |
| 2021-08-10 | Baeuerle Patrick See Remarks | Sale | −11,000 | $27.00 | $297K | 0 |
| 2021-08-10 | Baeuerle Patrick See Remarks | Option exercise · Stock Option (Right to Buy) | −11,000 | 251,114 | ||
| 2021-08-10 | Zawel Leigh See Remarks | Sale | −1,906 | $26.50 | $51K | 126,650 |
| 2021-08-10 | Zawel Leigh See Remarks | Sale | −3,191 | $27.34 | $87K | 123,459 |
| 2021-08-10 | Zawel Leigh See Remarks | Sale | −1,817 | $28.49 | $52K | 121,642 |
| 2021-08-09 | Zawel Leigh See Remarks | Sale | −19,504 | $26.52 | $517K | 130,256 |
| 2021-08-09 | Zawel Leigh See Remarks | Sale | −1,700 | $27.11 | $46K | 128,556 |
| 2021-08-09 | Zawel Leigh See Remarks | Sale | −19,504 | $26.52 | $517K | 130,256 |
| 2021-08-09 | Zawel Leigh See Remarks | Sale | −1,700 | $27.11 | $46K | 128,556 |
| 2021-01-12 | UBS Oncology Impact Fund L.P. 10% owner | Conversion | +1,136,525 | 1,136,525 | ||
| 2021-01-12 | UBS Oncology Impact Fund L.P. 10% owner | Conversion | +3,551,640 | 4,688,165 | ||
| 2021-01-12 | UBS Oncology Impact Fund L.P. 10% owner | Conversion | +2,276,692 | 6,964,857 | ||
| 2021-01-12 | UBS Oncology Impact Fund L.P. 10% owner | Conversion | +649,030 | 7,613,887 | ||
| 2021-01-12 | UBS Oncology Impact Fund L.P. 10% owner | Purchase | +300,000 | $21.00 | $6.3M | 7,913,887 |
| 2021-01-12 | UBS Oncology Impact Fund L.P. 10% owner | Conversion · Series Seed Convertible Preferred Stock | −1,136,525 | 0 | ||
| 2021-01-12 | UBS Oncology Impact Fund L.P. 10% owner | Conversion · Series A Convertible Preferred Stock | −3,551,640 | 0 | ||
| 2021-01-12 | UBS Oncology Impact Fund L.P. 10% owner | Conversion · Series B Convertible Preferred Stock | −2,276,692 | 0 |
Page 20 of 23 · 446 trades